Drug Trial Radar · NCT05396235
A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males
Last checked: Nov 20, 2026Latest source record: Jan 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Aug 3, 2022
Primary completion
Dec 24, 2022
Study completion Dec 24, 2022
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- May 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics when MT-3921 or a placebo is intravenously given to Japanese healthy adult male subjects
Conditions
- Healthy Adult Males
Interventions
MT-3921Biological
Solution for infusion; Intravenous (IV)
PlaceboBiological
Solution for infusion; Intravenous (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with adverse eventsTime frame: 16 weeks
- Percentage of subjects with adverse reactionsTime frame: 16 weeks
- Time course of serum concentrations of MT-3921Time frame: Day 1, 2, 3, 4, 8, 15, 29, 57, 85, and 113.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Research Hospital Tokyo
Shinjuku-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.